NCT04466618

Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes

To Determine the Effect of Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: Adrian Vella · Academic / Other
• Sex: All
• Age: 25 Years – 65 Years
• Healthy volunteers: Accepted

Summary

GLP-1 is a hormone made by the body that promotes the production of insulin in response to GLP-1 is produced within the islets expressing prohormone convertase 1/3eating. However, there is increasing evidence that this hormone might help support the body's ability to produce insulin when diabetes develops. The purpose of this study is to determine the effect of endogenous GLP-1 secretion on insulin secretion in people with and without type 2 diabetes.

Detailed description

Accumulating evidence suggests that in rodents and humans GLP-1 is synthesized within islets and may act locally in a paracrine fashion. Indeed, mice with genetic loss of intra-islet GLP-1 exhibit decreased insulin secretion and impaired response to metabolic stressors. 'Pancreatic' GLP-1 may contribute to the effects of DPP-4 inhibitors in rodents and humans. Antagonism of GLP1R with exendin-9,39 during fasting impairs the islet cell response to an I.V. glucose challenge. Islet GLP-1 content is increased in T2DM and in islets from non-diabetic humans exposed to hyperglycemia and Free Fatty Acids. These observations imply that paracrine GLP-1 secretion supports islet function in the presence of glucolipotoxicity. In this experiment we will examine the role of endogenous GLP-1 secretion in people with and without T2DM and during β-cell stress induced by FFA elevation.

Conditions

• Healthy
• Type 2 Diabetes

Interventions

Type	Name	Description
BIOLOGICAL	Saline	Saline infused during the study
BIOLOGICAL	Exendin-9,39	Exendin-9,39 infused during the study
BIOLOGICAL	Saline + Intralipid/Heparin	Saline infused during acute insulin resistance
BIOLOGICAL	Exendin-9,39 + Intralipid/Heparin	Exendin-9,39 infused during acute insulin resistance

Timeline

• Start date: 2021-04-15
• Primary completion: 2022-12-15
• Completion: 2022-12-31
• First posted: 2020-07-10
• Last updated: 2023-12-26
• Results posted: 2023-12-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study